SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Office Coding for SOLIRIS

Find a sample CMS 1500 Form here.

Claims coding

ICD-9-CM is based on the World Health Organization's Ninth Revision, International Classification of Diseases (ICD-9). There is no specific code for paroxysmal nocturnal hemoglobinuria (PNH). Therefore, you may be required to use multiple diagnosis codes to accurately reflect the patient's particular disorders. Access specific diagnosis classifications and associated ICD-9 codes.

Each payor or plan may have different coding or form requirements for claim submissions. Alexion recommends that you confirm this information prior to submitting a claim for SOLIRIS® (eculizumab). Until SOLIRIS is assigned its own Healthcare Common Procedural Coding System (HCPCS) J-code, payors will require that you use a miscellaneous code to designate the drug.

Office Coding for SOLIRIS

Next: Hospital Coding for SOLIRIS

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.